We report, using data from the I-SPY trial, that breast cancer patients with tumors showing low IGFBP7 gene expression were more than twice as likely to achieve a pCR with neoadjuvant treatment using the combination of ganitumab/metformin, and chemotherapy compared to neoadjuvant chemotherapy alone. The gene discussed is IGFBP7; the disease is breast carcinoma.